Litigation Details for SYNGENTA CROP PROTECTION, LLC v. WILLOWOOD, LLC (M.D.N.C. 2015)

SYNGENTA CROP PROTECTION, LLC v. WILLOWOOD, LLC (M.D.N.C. 2015)

Docket		Date Filed	2015-03-27
Court	District Court, M.D. North Carolina	Date Terminated	2017-11-20
Cause	15:1126 Patent Infringement	Assigned To	Catherine Caldwell Eagles
Jury Demand	Both	Referred To	Joi Elizabeth Peake
Patents	10,183,020
Link to Docket	External link to docket

Details for SYNGENTA CROP PROTECTION, LLC v. WILLOWOOD, LLC (M.D.N.C. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-27				External link to document

Syngenta Crop Protection v. Willowood Litigation Summary: Azoxystrobin Process Patent, Infringement Findings, and Generic Crop-Protection Entry

Last updated: August 6, 2026

Syngenta Crop Protection, LLC v. Willowood, LLC, No. 1:15-cv-00274-RGA, was a Delaware patent dispute over Willowood’s manufacture and sale of generic azoxystrobin fungicides. Syngenta asserted U.S. Patent No. 8,410,659, which covered a process for preparing azoxystrobin, the active ingredient marketed in products such as Quadris and Amistar.

The case produced a jury verdict for Syngenta, a damages award, post-trial rulings, and Federal Circuit review. The appellate court upheld the core infringement judgment in 2019. The dispute is important because Syngenta relied on a manufacturing-process patent after the principal compound-level exclusivity for azoxystrobin had expired or was no longer sufficient to block competing products.

What was Syngenta Crop Protection v. Willowood about?

The case concerned whether Willowood’s azoxystrobin manufacturing process infringed Syngenta’s process patent.

Azoxystrobin is a broad-spectrum strobilurin fungicide used on agricultural crops. Syngenta commercialized the compound under several brands and held intellectual-property rights covering the compound, formulations, manufacturing methods, and related uses. Willowood entered the market with lower-cost azoxystrobin products and sourced or manufactured the active ingredient through a process Syngenta alleged was covered by the ’659 patent.

Syngenta filed the action in the U.S. District Court for the District of Delaware in 2015. The case was assigned to Judge Richard G. Andrews.

Case profile

Item	Detail
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:15-cv-00274-RGA
Plaintiff	Syngenta Crop Protection, LLC
Defendants	Willowood, LLC and related Willowood entities
Principal product	Azoxystrobin fungicides
Principal patent	U.S. Patent No. 8,410,659
Patent subject matter	Process for preparing azoxystrobin
Federal Circuit appeal	944 F.3d 1344
Regulatory framework	EPA pesticide registration under FIFRA
FDA Orange Book relevance	None

What patent protected Syngenta’s azoxystrobin manufacturing process?

U.S. Patent No. 8,410,659 was the principal patent at issue. The patent covered a process for producing azoxystrobin through chemical steps involving an intermediate and specified reaction conditions.

The patent was strategically important because a process patent can restrict commercial supply even after a compound patent expires. A generic manufacturer may avoid a composition-of-matter patent by using a different synthesis route, but that route still creates infringement exposure if it falls within a valid process claim.

The litigation focused on claim scope, claim construction, infringement, validity, and the application of the doctrine of equivalents. The dispute was not limited to whether Willowood sold azoxystrobin. It turned on how Willowood made the active ingredient and whether its process satisfied the limitations of the asserted patent claims.

Patent and exclusivity implications

The ’659 patent did not operate like an FDA-listed drug patent. Agricultural pesticides are regulated by the Environmental Protection Agency under FIFRA rather than by FDA’s abbreviated new drug application system. Syngenta therefore could not rely on an Orange Book listing or a Paragraph IV certification to enforce the patent.

The commercial restriction arose from ordinary patent-infringement litigation and the possibility of an injunction, damages, or a negotiated supply and launch arrangement.

What did the Delaware district court decide?

The district court entered judgment for Syngenta after determining that Willowood infringed the ’659 patent. The court also rejected Willowood’s principal invalidity defenses.

The infringement dispute involved differences between Syngenta’s patented process and Willowood’s process. Willowood argued that its route did not practice the required claim limitations and that the patent could not be expanded through the doctrine of equivalents. Syngenta argued that the accused process performed substantially the same chemical function in substantially the same way to obtain substantially the same result.

The district court accepted Syngenta’s infringement position. The case proceeded to damages, with Syngenta receiving a monetary award tied to Willowood’s infringing sales.

Public reports concerning the case describe the damages award as approximately $19 million. The court also granted relief directed at continued infringement, subject to the appellate proceedings and later case developments.

Main district-court issues

The district court addressed:

1. The construction of the asserted process claims.
2. Whether Willowood’s manufacturing route met the claim limitations.
3. Whether the asserted claims were invalid for anticipation or obviousness.
4. Whether the doctrine of equivalents applied.
5. The proper measure of damages.
6. Whether Syngenta was entitled to injunctive relief or other post-trial remedies.

The case illustrates the commercial value of process patents in markets where the active ingredient is no longer protected by a broad compound patent.

What did the Federal Circuit decide in Syngenta v. Willowood?

The Federal Circuit affirmed the core judgment in Syngenta’s favor in Syngenta Crop Protection, LLC v. Willowood, LLC, 944 F.3d 1344 (Fed. Cir. 2019).

The appellate court reviewed the claim construction, infringement analysis, and validity findings. It upheld the district court’s treatment of the asserted patent claims and left the infringement judgment standing.

The Federal Circuit’s decision confirmed that Willowood’s process fell within the enforceable scope of the ’659 patent. The ruling also rejected Willowood’s attempt to avoid liability based on the chemical and procedural differences between its process and the process described in the patent.

Why the appellate ruling mattered

The Federal Circuit decision had four commercial effects:

• It preserved Syngenta’s ability to enforce the process patent against Willowood’s azoxystrobin supply chain.
• It confirmed that a manufacturing route can infringe even when the accused process differs in particular reagents or operating details.
• It increased the legal risk associated with importing or selling active ingredient manufactured through the accused process.
• It reinforced the importance of process patents after compound-level exclusivity declines.

The Federal Circuit did not create an Orange Book-style regulatory barrier. Its ruling was a conventional patent decision that affected the legal availability of the accused manufacturing route.

Did Willowood challenge the patent’s validity?

Yes. Willowood contested the validity and enforceability of Syngenta’s asserted patent claims.

The principal defenses in a process-patent case of this type include anticipation, obviousness, written description, enablement, and prosecution-history limitations. The district court rejected Willowood’s invalidity defenses, and the Federal Circuit left the relevant judgment in place.

The outcome gave Syngenta a valid and enforceable process patent for purposes of the asserted claims during the relevant period. It did not mean that every process for producing azoxystrobin was covered. The decision was claim-specific and depended on the scope of the ’659 patent and the technical evidence concerning Willowood’s process.

Was this a Paragraph IV challenge or Orange Book patent case?

No. The case was not an ANDA litigation under the Hatch-Waxman Act.

Azoxystrobin is an agricultural fungicide, not an FDA-approved human or animal drug. Agricultural pesticide products are registered with EPA under FIFRA. Consequently:

• There was no FDA Orange Book listing at issue.
• There was no Paragraph IV certification.
• There was no 30-month Hatch-Waxman stay.
• There was no FDA generic-drug approval timeline comparable to an ANDA case.
• The relevant regulatory question was EPA registration, not FDA approval.

Willowood’s ability to sell an EPA-registered product did not eliminate patent risk. Regulatory registration and patent freedom to operate are separate questions.

What litigation risks did Willowood face?

Willowood faced three principal risks: damages, injunctive relief, and supply-chain disruption.

Damages exposure

Syngenta sought compensation for infringing sales. The damages analysis depended on the accused products, the period of infringement, Syngenta’s licensing position, and the value of the patented process. Process-patent damages can be difficult to calculate because the patented manufacturing step may represent only part of the value of the finished pesticide.

Injunction risk

An injunction could have prevented Willowood from continuing to sell products made through the infringing process. For a pesticide manufacturer, that remedy can affect:

• EPA-registered product sales;
• inventory already imported into the United States;
• contracts with distributors;
• crop-season supply commitments;
• manufacturing arrangements with overseas suppliers.

Alternative-process risk

Willowood’s most commercially important pathway was adoption of a noninfringing manufacturing route. That option would require technical validation, supply qualification, regulatory review where applicable, and additional freedom-to-operate analysis. A process change could also affect cost, yield, impurity profiles, and product consistency.

How strong was Syngenta’s azoxystrobin patent estate?

Syngenta’s estate was strongest where it combined several layers of protection:

Protection layer	Strategic value
Compound patents	Broad protection for azoxystrobin, subject to expiration
Process patents	Protection against particular manufacturing routes
Formulation patents	Potential protection for product composition and delivery
Method-of-use patents	Potential protection for specified agricultural applications
Regulatory data rights	Protection connected to pesticide registration data
Trademarks and brands	Commercial differentiation after patent expiry

The Willowood case demonstrates that the process layer remained commercially relevant after competitors could pursue azoxystrobin products. The enforceability of that layer depended on the precise claim language and the technical operation of the accused process.

No FDA biosimilar risk existed because azoxystrobin is a small-molecule pesticide. The competitive threat was generic crop-protection entry, often involving Chinese or other non-U.S. manufacturing sources, rather than biosimilar substitution.

What was the competitive impact on azoxystrobin manufacturers?

Syngenta’s enforcement action increased entry costs for companies seeking to sell azoxystrobin products in the United States.

Competitors had several possible strategies:

1. Use a licensed Syngenta supply route.
2. Develop a process outside the ’659 patent claims.
3. Challenge the patent in litigation.
4. Wait for patent expiration.
5. Sell products in jurisdictions where the patent had expired or was not in force.
6. Pursue a settlement with defined supply or launch terms.

The case also gave Syngenta leverage in commercial negotiations with generic manufacturers and distributors. A successful process-patent case can preserve price and market-share protection even when the active ingredient itself is widely available.

What is the current litigation and exclusivity significance?

The principal legal significance of the case is historical and strategic. The Federal Circuit’s 2019 decision upheld Syngenta’s infringement position concerning the asserted process patent.

The case does not establish that Syngenta has perpetual exclusivity for azoxystrobin. Patent rights are territorial and term-limited. A company assessing current entry must separately review:

• the expiration status of the ’659 patent;
• continuation and divisional patents;
• foreign counterparts;
• EPA registrations;
• data-compensation rights;
• current Syngenta-Willowood agreements;
• later patents covering formulations or uses;
• any redesign of the manufacturing process.

The case number alone does not establish the status of later settlements, licenses, or post-judgment commercial arrangements.

Key Takeaways

• Syngenta sued Willowood over the manufacture and sale of azoxystrobin fungicides.
• U.S. Patent No. 8,410,659 was the central asserted patent.
• The patent covered a process for preparing azoxystrobin rather than an FDA-regulated drug product.
• The district court found infringement and rejected Willowood’s principal defenses.
• The Federal Circuit affirmed the core judgment in 2019 in 944 F.3d 1344.
• The dispute was not an Orange Book or Paragraph IV case.
• EPA pesticide registration did not provide freedom to operate under Syngenta’s patent.
• The case shows how process patents can delay or increase the cost of generic crop-protection entry after compound-level exclusivity weakens.
• Current freedom-to-operate analysis requires review of the ’659 patent, related patent families, foreign rights, EPA registrations, and any later commercial agreements.

FAQs About Syngenta v. Willowood

What product did Willowood sell in the Syngenta patent case?

Willowood sold generic azoxystrobin fungicides, which compete with Syngenta products containing the same active ingredient.

Was Syngenta’s patent an agricultural formulation patent?

The principal patent in the case, U.S. Patent No. 8,410,659, was directed to a manufacturing process for azoxystrobin. It was not primarily an FDA drug formulation patent.

Did the Federal Circuit reverse Syngenta’s infringement victory?

No. The Federal Circuit’s 2019 decision upheld the core infringement judgment in Syngenta’s favor.

Can a pesticide company avoid infringement by changing its manufacturing plant?

Not automatically. A new plant or supplier may still use a process covered by the patent. The chemical route, intermediates, reagents, and operating steps must be evaluated against the asserted claims.

Does this case affect azoxystrobin sales outside the United States?

U.S. litigation directly concerns U.S. patent rights. Foreign commercial exposure depends on separate national patents, their expiration dates, local registration rules, and the location of manufacture and sale.

References

1. Syngenta Crop Protection, LLC v. Willowood, LLC, 944 F.3d 1344 (Fed. Cir. 2019).

2. U.S. Patent No. 8,410,659. Process for the preparation of azoxystrobin. U.S. Patent and Trademark Office.

3. U.S. Environmental Protection Agency. (n.d.). Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA).

4. U.S. District Court for the District of Delaware. Syngenta Crop Protection, LLC v. Willowood, LLC, No. 1:15-cv-00274-RGA. Docket records.